LONG-TERM MORTALITY FOLLOW-UP OF ARMY RECRUITS WHO RECEIVED ADJUVANT INFLUENZA-VIRUS VACCINE IN 1951-1953
LONG-TERM MORTALITY FOLLOW-UP OF ARMY RECRUITS WHO RECEIVED ADJUVANT INFLUENZA-VIRUS VACCINE IN 1951-1953
复制标题
DOI：
10.1093/oxfordjournals.aje.a121402
复制
发表时间：
1972-01-01
影响因子：
5
通讯作者：
VIVONA, S
中科院分区：
文献类型：
--
作者：
BEEBE, GW;SIMON, AH;VIVONA, S
Beebe，G. W.（华盛顿国家研究理事会后续机构，D.C. 20418），A. H. Simon和S. Vivona. 1951- 1953年接受辅助流感病毒疫苗的陆军新兵的长期死亡率随访。美国流行病学杂志95：337-346，1972。虽然由流感委员会、武装部队流行病学委员会赞助的研究表明，在轻质矿物油中乳化可大大提高流感病毒疫苗的有效性，但由于担心油佐剂制剂的安全性，在对乳化剂（Arlacel A）和矿物油（Drakeol）在实验动物中进行长期试验之前，不能接受其常规使用。在之前的一项基于Salk 1951-1953年在Ft. Dix，没有迹象表明佐剂可导致死亡率效应。在本研究中，死亡率随访延长至1969年4月，即接种疫苗后16至18年。疫苗组与死亡证明、尸检方案和临终医院记录上列出的所有诊断进行了比较。对于恶性肿瘤、过敏性疾病和胶原蛋白疾病，结果基本上是阴性的。此外，没有证据表明已知在接种部位发生囊肿样反应或认为发生了佐剂疫苗介导的过敏反应的男性有更高的死亡风险。
Beebe, G. W. (Follow-up Agency, National Research Council, Wash., D.C. 20418), A. H. Simon and S. Vivona. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951–1953.Am J Epidemiol95: 337–346, 1972.—Although studies sponsored by the Commission on Influenza, Armed Forces Epidemiological Board have shown that the effectiveness of influenza virus vaccine can be greatly increased by emulsification in light mineral oil, concern as to the safety of oil-adjuvant preparations has prevented their acceptance for routine use pending definitive long-term testing of both emulsifying agent (Arlacel A) and mineral oil (Drakeol) in experimental animals. In a previous 10-year follow-up study based on Salk's 1951–1953 randomized trials of the adjuvant influenza virus vaccine at Ft. Dix, there was no suggestion of a mortality effect attributable to the adjuvant. In the present study the mortality follow-up has been extended through April 1969, 16 to 18 years after vaccination. The vaccine groups have been compared with respect to all diagnoses listed on the death certificates, autopsy protocols, and terminal hospital records. The findings are essentially negative with respect to malignant neoplasms, allergic diseases, and collagen diseases. In addition, there is no evidence that men known to have had the cyst-like reaction at the site of the inoculation, or thought to have had allergic reactions mediated by the adjuvant vaccine, have experienced a higher mortality risk.